Publications by authors named "S Navardi"
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.
Sci Rep
October 2024
Article Synopsis
- - Multiple sclerosis is a serious condition, and the study compared the efficacy and safety of a biosimilar drug called Xacrel to the original drug, Ocrevus, in patients with Relapsing Multiple Sclerosis (RMS) over 96 weeks.
- - The main goal was to see if both drugs had similar effects on reducing annual relapse rates (ARR) at 48 weeks, while also assessing other factors like disability progression, MRI results, and safety.
- - Results showed that Xacrel was equivalent to Ocrevus in reducing ARR, with no significant differences in efficacy or safety observed during the trial, confirming Xacrel as a viable alternative to Ocrevus.
Objective: The time to diagnosis of multiple sclerosis (MS) is of great importance for early treatment, thereby reducing the disability and burden of the disease. The purpose of this study was to determine the time from the onset of clinical symptoms to the diagnosis of MS and to evaluate the factors associated with a late diagnosis in Iranian MS patients.
Methods: The present cross-sectional study was conducted on patients with MS who were registered in the National MS Registry System of Iran (NMSRI).
Data on perioperative risk stratification in patients with multiple sclerosis (MS) are limited. In this regard, the present study was conducted to investigate Iranian specialists' approach to surgical counseling for patients with MS (PwMS). 21 MS specialists were asked about 11 case scenarios with different MS disease statuses, disease-modifying therapies (DMTs), and urgency of the operation.
View Article and Find Full Text PDFPeople with multiple sclerosis (MS) and their physicians recognize cognitive retention as an important desired outcome of disease-modifying therapies (DMTs). In this study, we attempted to gather the opinions of Iranian MS experts regarding the treatment approach toward clinical cases with different physical and cognitive conditions. Opinions of 20 MS specialists regarding the best approach to 6 case scenarios (with different clinical, cognitive, and imaging characteristics) were gathered via a form.
View Article and Find Full Text PDFBackground: Ocrelizumab is a humanized antiCD20, thought to be a highly effective disease-modifying therapy (DMT). Its most frequent adverse effects are infusion-related reactions (IRRs). To reduce these reactions, the first dose of ocrelizumab is administered as two 300 mg infusions separated by two weeks.
View Article and Find Full Text PDF